EGFR and non-small cell lung carcinoma: Furthermore, a phase III randomized trial (CTONG 0901) was conducted to analyze the relationship between TP53 and EGFR-TKIs in EGFR-mutated advanced NSCLC; the study found that the TP53 wild-type group had the longest median PFS (9.4 vs. 11.0 vs. 14.5 months, p = 0.009) and OS (15.8 vs. 20.0 vs. 26.1 months, p = 0.004) compared to exon 4 or 7 of TP53 or other TP53 mutations, indicating that TP53 could be a promising predictive and prognostic factor in EGFR-mutated NSCLC (21).